Adenylate cyclase type 9 (ADCY9)

Adenylate cyclase type 9 (ADCY9) is a membrane-bound enzyme catalyzing the conversion of ATP to cyclic AMP (cAMP), a central second messenger in cellular signal transduction. ADCY9 is widely expressed, especially in heart, lung, immune cells, and the brain. It operates downstream of G protein-coupled receptors and protein kinases, and is selectively activated by beta-adrenergic signaling but is forskolin-insensitive. ADCY9 is crucial for regulation of cardiac ion channels (via complexing with AKAP9/Yotiao and modifying potassium channel KCNQ1), immune cell polarization and trafficking, T cell regulation, cancer cell proliferation and apoptosis, and bronchial response to therapy. Genetic variation in ADCY9 (particularly rs1967309) determines cardiovascular response to dalcetrapib (a CETP inhibitor). ADCY9 also plays roles in metabolic, respiratory, and autoimmune disease. Its multifunctional signaling properties make it a therapeutic target and pharmacogenomic biomarker across disease categories, though its tissue- and genotype-dependent roles present inherent safety and efficacy challenges in clinical interventions

Other names

Adenylate cyclase 9Adenylyl cyclase 9AC9ACIXKIAA0520ATP pyrophosphate-lyase 9Adenylate cyclase type IXAdenylyl cyclase type IXType IX ATP pyrophosphate-lyase

Dalcetrapib: Efficacy in cardiovascular prevention is determined by ADCY9 polymorphism; decreased ADCY9 activity (in AA genotype) is protective via increased cAMP and cholesterol efflux in macrophages.\nBeta-adrenergic agonists: Stimulate ADCY9 enzymatic activity, increasing cAMP biosynthesis, thereby modulating airway and cardiac function.\nMicroRNA targeting: Post-transcriptional modulation of ADCY9 in cancer and immune cells affects proliferation/apoptosis